Mr. Burgess has handled complex litigation matters in the Supreme Court; in the First, Second, Third, Fourth, Fifth, Sixth, Seventh, Ninth, D.C. and Federal Circuits; in several state appellate courts; in bankruptcy court; and in numerous federal and state trial courts.
Mr. Burgess has briefed and argued several significant recent appeals:
- Led successful appeal in the Third Circuit of adversary judgment in bankruptcy adversary action regarding the scope of a channeling injunction for asbestos claims under 11 U.S.C. 524(g). See In re: W.R. Grace & Co., 13 F. 4th 279 (3d Cir. 2021).
- Led appeal in the Federal Circuit on behalf of leading pharmaceutical company in Hatch-Waxman litigation challenging decision that claims on patents for the product Quillivant are non-obvious. No. 2021-1495 (decision pending).
- Successfully defended class-action settlement in antitrust litigation in the Second Circuit on appeal raising issue of first impression concerning the authority of claims administrators to opt customers out of class actions. See In re Aggrenox Antitrust Litig., 812 F. App’x 26 (2d Cir. 2020).
- Successfully represented the National Mining Association in the D.C. Circuit in defense of the decision by the Environmental Protection Agency not to finalize new “financial responsibility” requirements for the hardrock mining industry under Section 108(b) of CERCLA. Presented oral argument on behalf of coalition of industry intervenors. See Idaho Conservation League v. Wheeler, 930 F.3d 494 (D.C. Cir. 2019).
- Persuaded the U.S. Supreme Court to grant certiorari in two matters in the 2019 Term, led merits briefing, and presented oral argument. Secured 7-2 decision for a habeas petitioner, in a decision holding that restrictions on second or successive habeas petitions are not applicable to timely motions for reconsideration under Rule 59(e). See Banister v. Davis, 140 S. Ct. 1698 (2020).
- Successfully defended judgment for BarBri, Inc. in affirmance of claims brought by a bar-exam competitor under the Sherman Act and RICO. Mr. Burgess co-authored motion to dismiss briefing in litigation in the Southern District of New York, and then led successful appellate effort in the Second Circuit. See LLM Bar Exam, LLC v. BarBri, Inc., 922 F.3d 136 (2d Cir. 2019).
- Successfully defended post-trial JMOL for DCo LLC in the Ninth Circuit in wrongful death action based on alleged asbestos exposure. See Jack v. DCo LLC et al., 837 F. App’x 421 (9th Cir. 2021).
- Successfully represented client in the D.C. Circuit in a litigation that resulted in the dismissal of a challenge to a shipping client’s eligibility to participate in the “Maritime Security Program” administered by the Maritime Administration and the Department of Defense. See Matson Navigation Co. v. U.S. Dep’t of Transp., 895 F.3d 799 (D.C. Cir. 2018).
- Persuaded the Washington Court of Appeals to grant interlocutory review and then reverse the denial of clients’ motion for summary judgment in product liability case involving the prescription drug metoclopramide. The decision rejected an effort by the plaintiff to expand the scope of a drug company’s duty to warn under state law to extend beyond the warnings provided with a product’s package insert. See Sherman v. Pfizer, Inc., P.3d, 2019 WL 1923583 (Wash. App. 2019).
Mr. Burgess’s FDA litigation matters include:
- Leading litigation on behalf of pharmaceutical company as intervenor defending against challenge to approval of section 505(b)(2) application premised on a challenge to the FDA’s classification of a product as a drug rather than a biologic. See Ipsen Biopharm., Inc. v. Becerra, No. 22-cv-860 (D.D.C.).
- Led challenge on behalf of e-cigarette manufacturer to challenge an FDA marketing denial. See Breeze Smoke, LLC v. FDA, 18 F. 4th 499 (6th Cir. 2021).
- Led litigation on behalf of pharmaceutical company as intervenor defending award of 180-day exclusivity for application to market generic buprenorphine film against forfeiture challenge by competitor. See Alvogen, Inc. v. Becerra et al., No. 21-cv-672 (D.D.C.).
- Representing pharmaceutical company in action challenging FDA award of NCE exclusivity. See Sandoz v. Becerra et al., No. 21-cv-600 (D.D.C.)
- Represented pharmaceutical company in challenge to approval of 505(b)(2) application brought by competitor asserting that NCE exclusivity barred receipt of application and approval. See Genus Lifesciences, Inc. v. Becerra et al., No. 20-cv-211 (D.D.C.).
- Co-authored brief in D.C. Circuit on behalf of a pharmaceutical company defending approval of its new drug application against a competitor’s exclusivity challenge. The D.C. Circuit upheld FDA’s approval of our client’s application in a decision that set an important precedent on the scope of 3-year exclusivities for new clinical investigations. See Otsuka Pharm. Co. v. Price, 869 F.3d 987 (D.C. Cir. 2017).
- Co-authored briefs on behalf of a leading pharmaceutical manufacturer and several other intervenors in a suit against FDA seeking to stop the launch of generic versions of the drug Abilify.® Successfully opposed a preliminary injunction and then obtained summary judgment.
Mr. Burgess’s other significant matters include:
- Led merits briefing in several matters in the U.S. Supreme Court. Co-authored brief and served as second-chair in Supreme Court litigation concerning the test for whether an artistic design feature can qualify for a copyright. Mr. Burgess represented the copyright owner, which designed original artwork appearing on clothing. The Supreme Court held by a vote of 6-2 that the designs were copyright-eligible. Star Athletica, LLC v. Varsity Brands, Inc., 137 S. Ct. 1002 (2017). Also co-authored merits brief in Washington v. United States on behalf of a group of Tribes, in which the Supreme Court affirmed a lower-court injunction requiring the State to replace culverts that blocked salmon passage in violation of tribal fishing rights protected by treaty.
- Co-authored briefs in the Second Circuit on behalf of a major banking client in a putative class-action alleging violations of the Racketeering Influenced and Corrupt Organizations Act based on the rates charged for lender-placed insurance. Successfully obtained interlocutory review and reversal of adverse judgment resulting in an order to dismiss all claims. See Rothstein v. Balboa Insurance Company, 794 F.3d 256 (2d Cir. 2015).
- Has defended a leading pharmaceutical manufacturer in several putative class actions challenging patent litigation settlements on antitrust grounds, initiated after the Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013). Co-authored motions to dismiss briefs in complex multidistrict litigation resulting in dismissal of several claims and complete dismissal of claims against the parent corporation. Led briefing on oppositions to class certification.
- Co-authored several briefs in opposition to petition for certiorari in the Supreme Court, including a brief in a First Amendment challenge to a transit authority’s advertising policy, a brief concerning the rules for claim construction in patent litigation, and a brief in a Sixth Amendment sentencing case in opposition to the Michigan Attorney General.
- Successfully led arbitration on behalf of insurance client in defense against breach of contract in settlement agreement entered in connection with an asbestos bankruptcy.
- Presented oral argument and successfully persuaded the Fourth Circuit to vacate in a pro bono matter challenging a county’s anti-panhandling ordinance as inconsistent with the First Amendment. See Reynolds v. Middleton, 779 F.3d 222 (4th Cir. 2015).